HIV-associated lipodystrophy is an as yet undefined syndrome that may include
hypertriglyceridemia, insulin resistance, diabetes, dorsocervical fat accumulation (buffalo …

HIV-associated lipodystrophy, first described in 1998 [1], is characterized by peripheral
lipoatrophy of the face, limbs and buttocks, and central fat accumulation within the abdomen …

The HIV associated lipodystrophy syndrome is characterized by fat loss from the periphery,
fat accumulation in the abdominal, dorsocervical regions and breasts, and hyperlipidaemia …

Objectives: Identify the etiology of HIV-associated lipodystrophy. Describe the typical
physical exam of a patient with HIV-associated lipoatrophy. Review the treatment and …

HIV-associated lipodystrophy is clinically characterized by body fat changes including
subcutaneous fat loss (lipoatrophy) with or without truncal fat accumulation …

Treatment with highly active antiretroviral therapy (HAART) has been implicated in the
development of anthropomorphic and metabolic abnormalities termed HIV lipodystrophy …

Human immunodeficiency virus (HIV)–associated lipodystrophy refers to fat accumulation,
also known as lipohypertrophy, and fat wasting, also known as lipoatrophy. Both conditions …

BACKGROUND HIV-infected individuals are living long, healthy lives. They are now
concerned with less life-threatening problems, especially lipodystrophy. OBJECTIVE To …

Body composition alterations are common in HIV infection and include AIDS wasting and
lipodystrophy. Both are associated with metabolic alterations, including hypertriglyceridemia …

Approximately 50% of patients on highly active antiretroviral therapy (HAART) develop
lipodystrophy with central and visceral fat accumulation and/or facial and limb atrophy …